Cefuroxime detailed information

Jump to: navigation, search
Cefuroxime detailed information
Cefuroxime.png
Clinical data
Routes of
administration
oral, intramuscular, intravenous
ATC code
Pharmacokinetic data
Bioavailability37% on empty stomach, up to 52% if taken after food
Metabolismaxetil moiety is metabolized to acetaldehyde and acetic acid
Elimination half-life80 minutes
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC16H16N4O8S
Molar mass424.386 g/mol

WikiDoc Resources for Cefuroxime detailed information

Articles

Most recent articles on Cefuroxime detailed information

Most cited articles on Cefuroxime detailed information

Review articles on Cefuroxime detailed information

Articles on Cefuroxime detailed information in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cefuroxime detailed information

Images of Cefuroxime detailed information

Photos of Cefuroxime detailed information

Podcasts & MP3s on Cefuroxime detailed information

Videos on Cefuroxime detailed information

Evidence Based Medicine

Cochrane Collaboration on Cefuroxime detailed information

Bandolier on Cefuroxime detailed information

TRIP on Cefuroxime detailed information

Clinical Trials

Ongoing Trials on Cefuroxime detailed information at Clinical Trials.gov

Trial results on Cefuroxime detailed information

Clinical Trials on Cefuroxime detailed information at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cefuroxime detailed information

NICE Guidance on Cefuroxime detailed information

NHS PRODIGY Guidance

FDA on Cefuroxime detailed information

CDC on Cefuroxime detailed information

Books

Books on Cefuroxime detailed information

News

Cefuroxime detailed information in the news

Be alerted to news on Cefuroxime detailed information

News trends on Cefuroxime detailed information

Commentary

Blogs on Cefuroxime detailed information

Definitions

Definitions of Cefuroxime detailed information

Patient Resources / Community

Patient resources on Cefuroxime detailed information

Discussion groups on Cefuroxime detailed information

Patient Handouts on Cefuroxime detailed information

Directions to Hospitals Treating Cefuroxime detailed information

Risk calculators and risk factors for Cefuroxime detailed information

Healthcare Provider Resources

Symptoms of Cefuroxime detailed information

Causes & Risk Factors for Cefuroxime detailed information

Diagnostic studies for Cefuroxime detailed information

Treatment of Cefuroxime detailed information

Continuing Medical Education (CME)

CME Programs on Cefuroxime detailed information

International

Cefuroxime detailed information en Espanol

Cefuroxime detailed information en Francais

Business

Cefuroxime detailed information in the Marketplace

Patents on Cefuroxime detailed information

Experimental / Informatics

List of terms related to Cefuroxime detailed information


Cefuroxime is a second-generation cephalosporin antibiotic that has been widely available in the USA since 1977. It is also available under the brand name Ceftin. Glaxo Smith Kline sells the antibiotic in Australia (and other countries, such as Israel) under the name Zinnat (R)[1], with the Australian pharmaceutical code of R 47621. In Poland it is produced by the Polish firm Bioton S.A. under the name Biofuroksym®.[2]

According to the package insert supplied with Zinnat, Cefuroxime is manufactured as tablets as well as a sodium salt, the latter designed for medical injection.

Indications

As for the cephalosporins, although as a second-generation it is less susceptible to Beta-lactamase and so may have greater activity against Haemophilus influenzae, Neisseria gonorrhoeae and Lyme disease.

Side effects

Cefuroxime is generally well tolerated and side effects are usually transient. Cefuroxime if taken with food is both better absorbed and less likely to cause its commonest upsets of diarrhea, nausea, vomiting and abdominal pain.

Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, an article in the Journal of Family Practice (February 2006)[3] has shown no increased risk for cross-allergy for cefuroxime and several other 2nd generation or later cephalosporins.

References

  1. Zinnat entry on the Glaxo Smith Kline website.
  2. Jędrzejczyk, Tadeusz. "Internetowa Encyklopedia Leków". leki.med.pl. Retrieved 2007-03-03.
  3. http://www.jfponline.com/pdf%2F5502%2F5502JFP_AppliedEvidence1.pdf

fa:سفوروکسیم no:Cefuroksim th:เซฟูรอกซิม



Linked-in.jpg